FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 20, 2024
BIOADAPTIVES, INC. |
(Exact Name of Registrant as Specified in its Charter) |
Delaware | | 000-54949 | | 46-2592228 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
2620 Regatta Drive, Suite 102
Las Vegas, Nevada 89128
(Address of Principal Executive Office) (Zip Code)
(702) 659-8829
Registrant's telephone number, including area code:
N/A
(former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 20, 2024, the Shareholders of BioAdaptives Inc accepted the resignation of the Chairman of the Board Edward Jacobs for personal reasons and the resignation of Board Member Robert Ellis also for personal reasons. In the same meeting, the Shareholders elected James Keener as Chairman of the Board and currently the sole Member of the Board.
On May 20, 2024, following the shareholders meeting the Board of Directors of BioAdaptives Inc met and accepted the resignation of the CEO Edward Jacobs for personal reasons and the resignation of President Robert Ellis also for personal reasons. The Board of Directors then elected James Keener to the position of CEO and currently the sole Officer.
Item 7.01 Regulation FD Disclosure
The Company issued a press release on May 21, 2024, announcing the departure of Dr .Edward Jacobs, Jr and Mr Robert Ellis and the appointment of Mr. James Keener as the Company’s Director and CEO.
A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| May 22, 2024 | | BioAdaptives, Inc. | |
| | | | |
| | /s/ James Keener | |
| | James Keener | |
| | Director and CEO | |
